News & Analysis as of

Biotechnology China

A Chinese healthcare boom

by Hogan Lovells on

Presenting a tremendous potential for growth fueled by domestic demographic and economic forces, China's healthcare industry has attracted notable PE investments in recent years. And with some commentators projecting that...more

Predictions and Outlook for U.S. Federal and International Chemical Regulatory Policy 2017

Predictions and Outlook for EPA’s Office of Chemical Safety and Pollution Prevention (OCSPP) 2017 - 2016 was full of surprises, two of which will drive much of the agenda for OCSPP during 2017. First, Congress...more

Donations and Grants in China: Compliance Controls Beyond T&E

by Ropes & Gray LLP on

While travel and entertainment expenses have presented significant compliance challenges for life sciences companies operating in China, donations and grants can also pose notable compliance risks. China’s escalated...more

Q1 2016 IPO Market Review

by WilmerHale on

The first quarter of 2016 produced a meager eight IPOs with gross proceeds of $667 million. Only once over the prior 12 years has the first quarter produced a lower tally—there were only two new offerings in the glum...more

Record breaker: US M&A in 2015

by White & Case LLP on

As the dust settles from the explosion of US M&A activity in 2015, it is fitting to reflect on the forces that fueled the boom and consider what last year’s trends may tell us about the year ahead. The record year...more

Australia Biotech Week showcases sophistication and growth

by Dentons on

On October 9, Australia's biotech community completed its annual pilgrimage to Melbourne at the conclusion of Australia Biotech Invest 2015 and AusBiotech 2015. This year's conferences once again evidenced the primacy and...more

Back in the game: The rise of US M&A

by White & Case LLP on

US M&A is bouncing back - After a tough few years, acquisitions in the United States have seen a remarkable resurgence - The first half of 2014 saw a great dealmaking revival in the United States. Deal values...more

US China Trade War Newsletter

by Dorsey & Whitney LLP on

Dear Friends, There have been major developments in the trade, solar cells, US/Chinese antitrust, and securities areas. REASON FOR THIS NEWSLETTER - Some readers have commented that this newsletter is...more

China’s Life Sciences Regulatory Crackdown: September 10 Update

by Reed Smith on

The regulatory enforcement environment in China remains tense, as both the Chinese government and media bring new actions and allegations against life sciences manufacturers in both the pharmaceutical and device sectors. We...more

Ten Required Steps To Ensure Effective Compliance Programs By Pharmaceutical And Medical Device Companies (Part III Of III)

by Michael Volkov on

In response to the Glaxo controversy and the continuing risks of aggressive FCPA enforcement, drug and device companies need to review and enhance their anti-corruption compliance programs. ...more

Pharmaceutical And Medical Device Companies: Taking It On The Chin (Part II Of III)

by Michael Volkov on

As the Glaxo controversy unravels each day, it is important to remember the enforcement context in which the current prosecution in China is occurring. ...more

China Strengthens Oversight of Human Subjects Research

by Ropes & Gray LLP on

On July 15, 2013, China National Health and Family Planning Commission (the “Commission”) published the draft Administrative Measures on Medical Research Involving Human Subjects (the “Draft Measures”) and is seeking public...more

Bad News For The Drug And Device Industries: Glaxo’s Systemic Breakdown In China (Part I Of III)

by Michael Volkov on

Mark Twain, one of my favorite authors, always said it best – “Do the right thing. It will gratify some people and astonish the rest.” - For drug and device companies, Mark Twain’s observation is becoming the industry...more

China Life Sciences Health Industry Client Briefing – May/June 2013 (July 12, 2013)

by Reed Smith on

Pharmaceuticals, Medical Devices, Health Care & Life Sciences - .. Medical Devices Regulations and News - Provincial FDAs to Approve Certain Changes to Medical Device Registration Certificates – June 21,...more

Mofo Tech -- Spring/Summer 2013

by Morrison & Foerster LLP on

In This Issue: - Here Come the Feds -- What President Obama’s second term means for the tech industry - Log In: ...Feds cast an eye on social media - Focus: ...3-D’s IP dimension -...more

China Life Sciences - January 2013

by Morrison & Foerster LLP on

In This Issue: Investor Q&A; Key Regulatory Issues for Strategic Life Sciences Partnerships in China; Compulsory Patent Licensing in China; and New Developments on the “Patentable Subject Matter” Requirement of U.S....more

Spread of Laboratory-generated Antibiotic Drug Resistance in Chinese Rivers

A generation ago, Jeremy Rifkin famously convinced the Cambridge city council to ban genetic engineering in that city, using the fear of "tinkering" with nature and producing a "superbug" that would hurt the public health and...more

17 Results
|
View per page
Page: of 1
Cybersecurity

"My best business intelligence,
in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!